Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence…

Locoregional RecurrenceHormone Receptor-positive Breast CancerHER2-negative Breast Cancer

Oana DanciuNCT05467891